Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07219030 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess the Adverse Events and How Oral Emraclidine Moves Through the Body of Healthy Elderly Adult Participants
A Phase 1 study of Healthy Volunteer, sponsored by AbbVie.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
- 4
- Study locations
NCT07219030: Recruiting Phase 1 study of Healthy Volunteer, sponsored by AbbVie.
NCT07219030 is a Phase 1 study of Healthy Volunteer that is actively recruiting participants, run by AbbVie. The registered enrollment target is 32 participants, below the 202-participant average among 112 other Healthy Volunteer trials with a reported enrollment target (84% lower). The trial reports 4 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07219030, a Phase 1 study of Healthy Volunteer, is actively recruiting participants, sponsored by AbbVie.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
- 4
- Study locations
Study Summary
This study is to assess how oral emraclidine moves through the body of healthy elderly adult participants, and assess adverse events, and tolerability.
Primary Outcome
An AE is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Emraclidine
Study Locations (4)
Florida
- K2 Medical Research, LLC /ID# 276636 - Maitland
- Clinical Pharmacology Of Miami /ID# 276856 - Miami
California
- Altasciences Clinical Los Angeles /ID# 276854 - Cypress
Illinois
- Acpru /Id# 276996 - Grayslake
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2025-10-08 |
| Est. Completion | 2026-11 |
| Phase | Phase 1 |
What NCT07219030 shows while recruiting
NCT07219030 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 202-participant average among 112 other Healthy Volunteer trials with a reported enrollment target (84% lower).
The record links to 1 condition, with Healthy Volunteer appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07219030 reports a single indexed study location in Florida, California, Illinois.
Frequently Asked Questions
What is clinical trial NCT07219030 about?
NCT07219030 is a clinical study titled "A Study to Assess the Adverse Events and How Oral Emraclidine Moves Through the Body of Healthy Elderly Adult Participants". This study is to assess how oral emraclidine moves through the body of healthy elderly adult participants, and assess adverse events, and tolerability.
What is the current status of trial NCT07219030?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2025-10-08. Estimated completion is 2026-11.
What conditions does trial NCT07219030 study?
This clinical trial studies the following conditions: Healthy Volunteer.
What interventions are being tested in trial NCT07219030?
The interventions under investigation include: Placebo (DRUG), Emraclidine (DRUG).
Who is sponsoring clinical trial NCT07219030?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07219030 being conducted?
This trial has 4 study locations across California, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy Volunteer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07219030's enrollment target sits among peer trials
32 73rd of 112 higher than 39 of 112 other Healthy Volunteer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Healthy Volunteer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Healthy Volunteer Study
RECRUITING · Phase 1
-
Neuropharmacologic Imaging and Biomarker Assessments of Response to Acute and Repeated-Dosed Ketamine Infusions in Major Depressive Disorder
RECRUITING · Phase 1
-
Role of Metal Ion Transporter ZIP8 in Alcohol-Related Behaviors
RECRUITING · Phase 1
-
A First-in-Human Single and Multiple Ascending Dose Study of MT-201
RECRUITING · Phase 1
-
A Study to Assess How the Drug Moves Through the Body, Adverse Events, and Tolerability of Oral ABBV-722 Capsules of Single and Multiple Ascending Doses in Adult Participants and Single Doses in Adult Asian Participants
RECRUITING · Phase 1
-
Safety and Immunogenicity of Ad4-HIV Envelope Vaccine Vectors in Healthy Volunteers
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI